Finanzen von InspireMD Inc (NSPR)NSPRInspireMD Inc

InspireMD Inc (NSPR) generates its revenue primarily from CGuard, which accounts for 100.0% of total sales, equivalent to $1.76M. Understanding this concentration is critical for investors evaluating how NSPR navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, InspireMD Inc maintains a gross margin of -43.70%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -815.64%, while the net margin is -808.81%. These profitability ratios, combined with a Return on Equity (ROE) of -202.81%, provide a clear picture of how effectively NSPR converts its operational activities into shareholder value.

In the context of the broader market, NSPR competes directly with industry leaders such as PAVM and SNWV. With a market capitalization of $41.41M, it holds a leading position in the sector. When comparing efficiency, NSPR's gross margin of -43.70% stands against PAVM's -269.70% and SNWV's 73.65%. Such benchmarking helps identify whether InspireMD Inc is trading at a premium or discount relative to its financial performance.

InspireMD reported Q1 2026 revenue of $3.4 million, a 120% increase year-over-year, but has also faced significant net losses, with a net income of -$14.32 million in Q2 2026. The gross margin has fluctuated, with a negative gross margin of -43.70% in Q2 2026, indicating financial instability.